Recent Updates — BPTH

Bio-Path Holdings, Inc. announced a strategic turnaround involving a pivot toward blockchain technology and digital asset management. The company acquired a majority stake in Himalaya Technologies, Inc., a crypto social site operator, through a $670,260 share issuance. It also engaged Farrington Capital Group to find strategic partners for its biotechnology assets and signed a letter of intent with altFINS to integrate AI-driven crypto analytics. Additionally, the Board approved a new class of 5,000,000 Series B Preferred shares. MD Anderson cancer center agreed to restart Phase 2 AML trials pending the settlement of $355,546.76 in outstanding dues. The company is a biotechnology firm developing drug therapies for cancer and other conditions.